In the news
In the news
Press Releases
02-13-2024
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
Read01-06-2024
Bayer and RTW Investments lead Series D financing in Chinese biotech Ji Xing Pharmaceuticals
Read11-09-2023
Bayer and Recursion focus research collaboration on Oncology
Read10-05-2023
65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in Singapore
Read08-29-2023
Gene Editing: Pairwise and Bayer start new five-year multi-million Dollar collaboration to further advance short-stature corn
Read
Press coverage of Leaps and portfolio companies
- The New York Times
- Ars Technica
February 01, 2024
The right bacteria turn farms into carbon sinks
- CNN
- MIT Tech Review
- Nature
July 17, 2023
Bat biotech takes flight
- Wired
May 18, 2023
The First CRISPR Edited Salad Is Here
Leaps events
Spotlight on Juergen Eckhardt
Juergen Eckhardt is EVP and Head of Leaps by Bayer, the impact investment arm, and Head of Business Development, & Licensing (BD&L) for the Pharmaceuticals division. He is a medical doctor and venture investor in healthcare, biotech, and agriculture with more than 20 years of experience. He is a strong believer that scientific breakthroughs can help us overcome some of humanity’s biggest challenges, including to cure and prevent chronic disease and to feed an ever-growing world population in a sustainable way – in short: science for a better life. He holds an MD from the University of Basel, Switzerland, and an MBA from INSEAD in Fontainebleau, France.
Read MoreOp-eds by Juergen Eckhardt
Documents
Explore the latest reports and publications developed by Leaps by Bayer and our collaborators.
Learn how to bring AgTech products from concept to market.
DownloadRead about our 2023 milestones, portfolio company highlights, engagement activities, and more.
DownloadSee how our 10 Leaps framework could generate return for humanity.
DownloadRead about our 2022 milestones, portfolio company highlights, engagement activities, and more.
DownloadRead about the work with our partners at the Happiness Research Institute.
Download
Press Kit
Leaps by Bayer is the impact investment arm of Bayer AG. We invest in teams pursuing fundamental breakthroughs in life science, targeting 10 huge challenges facing humanity.
Some call them impossible. We call them “Leaps”.
Media Contact
Kira Peikoff
Kira Peikoff is a former journalist who covered emerging biotechnologies for publications including The New York Times, Newsweek, and Popular Mechanics. She now leads communications for Leaps by Bayer.
Our return to humanity
The Leaps team brings together a diverse group of individuals with expertise in biotech, healthcare, agriculture, investment, and communication.